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Identity 
Other names: HNRNP-I, HNRNPI, HNRPI, PTB, 
PTB-1, PTB-T, PTB2, PTB3, PTB4, pPTB 




The PTBP1 locus spans 14936 bases on the short arm 
of chromosome 19 and is composed of 14 exons. 
Transcription 
PTBP1 results from skipping of exon 9 (3203 bp  
mRNA and 531 amino acid protein). Three additional 
isoforms are generated by alternative splicing: PTB2 
(3260 bp mRNA and 550 amino acid protein) and 
PTBP4 (3281 mRNA protein and 557 amino acid 
protein) derive from exon 9 inclusion using two 
alternative 3' splice sites, while PTB-T has been 
reported to result from alternative splicing of exons 2-
10 (Sawicka et al., 2004). 
Pseudogene 
PTBP1P (polypyrimidine tract binding protein 1 
pseudogene), chromosome location 14q23.3, starts at 
65745938 and ends at 65748375 bp from pter 
(according to hg19-Feb_2009). 
Protein 
Description 
57 kDa protein belonging to the heterogeneous nuclear 
ribonucleoprotein family (hnRNP). PTBP1 has four 
RNA recognition motifs (RRMs) and a conserved N-
terminal domain that harbors both nuclear localisation 
and export signals (NLS and NES).  
Through the RRMs, PTBP1 binds to the transcript at 
multiple sites within large pyrimidine tracts leading to 
conformational changes suitable for functional mRNA 
processing (Sawicka et al., 2004). 
 
 
Shematic representation of PTB mRNA alternative splicing. Alternative splicing of PTB mRNA, as described below, originates four 
isoforms. Green boxes represent exons and thin black lines represent introns (not to scale). 
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Schematic representation of PTBP1 protein structure. Each RNA recognition motif (RRM) has different binding affinity for pyrimidine-
rich sequences on mRNA. The N-terminal domain encloses partially overlapping nuclear localisation (NLS) and export signals (NES). 
Blue boxes representing RRMs are not drawn to scale. 
 
Expression 
PTBP1 is ubiquitously expressed in human tissues 
emerging as a pleiotropic splicing regulator. PTBP1 
expression levels have been associated with myoblast 
and neural precursor differentiation through specific 
modulation of the splicing pattern (Clower et al., 2010). 
In the brain, in particular, the switch from PTBP1 to 
nPTB expression drives the differentiation towards the 
neuronal lineage: PTBP1 is expressed in neural 
precursors and glial cells, while post-mitotic neurons 
express only nPTB (Boutz et al., 2007). Recently a 
strong PTBP1 expression has been found in embryonic 
stem cells, particularly those in the brain cortex and 
subventricular zone, where PTBP1 appears essential for 
cell division after implantation (Shibayama et al.,2009; 
Suckale et al., 2011). 
Localisation 
PTBP1 shuttles between the nucleus and the cytoplasm. 
Cytoplasmic localisation is mainly achieved by PKA-
mediated phosphorylation of a specific serine residue 
(Ser-16) within the nuclear localisation signal. 
Cytoplasmic accumulation of PTB occurs during cell 
stress (Sawicka et al., 2008). PTBP1 has also been 
identified as a key component in maintaining the 
integrity of the perinucleolar compartment, a sub-
nuclear structure predominantly found in transformed 
cells (Wang et al., 2003). 
Function 
PTB was originally identified as a regulator of 
alternative splicing (Garcia-Blanco et al., 1989) but 
other roles in mRNA processing have been described 
(Sawicka et al., 2008). 
Alternative splicing regulation: PTBP1 commonly 
acts as repressor of alternative splicing favouring 
skipping of alternative exons. Different models of 
PTBP1 activity have been proposed (Spellman and 
Smith, 2006): 1) binding competition with the splicing 
factor U2AF65 at the 3' splice site of alternative exons; 
2) polymerization of PTBP1 molecules on the 
alternative exon masking splicing enhancer sequences; 
and 3) looping out of alternative exon by PTBP1 
binding of flanking intronic sequences. Targets of 
PTBP1-mediated repression of exon inclusion comprise 
α-tropomiosin, α-actinin, GABAAγ2 (gamma-
aminobutyric acid Aγ2), c-src and FGFR2 (fibroblast 
growth factor receptor 2) (Li et al., 2007; Spellman et 
al., 2005). Recent evidences indicate that PTBP1 may 
also favour exon inclusion depending on the position of 
its binding sites relative to the target exon. Upon 
binding to the upstream intron and/or within the exon, 
PTBP1 represses exon inclusion, while by binding to 
the downstream intron, it activates exon inclusion. The 
PTBP1 position-dependent activity relies on the splice 
site features: in particular included exons show weaker 
5' splice sites, whereas skipped exons have longer 
polypyrimidine tracts (Llorian et al., 2010). 
PTBP1 pre-mRNA undergoes PTBP1-mediated 
alternative splicing too, as part of an autoregulatory 
feedback loop: high levels of PTBP1 induce skipping 
of exon 11 and hence mRNA degradation via the 
nonsense-mediated mRNA decay (Spellman et al., 
2005). 
3'-end processing: PTBP1 both promotes and inhibits 
the mRNA 3'-end cleavage required for 
polyadenylation. PTBP1 may prevent mRNA 
polyadenylation through competition with the cleavage 
stimulating factor (CstF), or stimulate polyadenylation 
by binding to pyrimidine-rich upstream elements 
(USEs). 
mRNA transport:  evidences for a role of PTBP1 in 
mRNA transport come from experiments in Xenopus, 
where the PTBP1 homologue (VgRBP60) is involved 
in the localisation of the Vg1 mRNA. In vertebrates 
PKA-activated PTBP1 is involved in α-actin mRNA 
localisation at neurite terminals. 
mRNA stability:  PTBP1 increases the stability of 
specific transcript by binding to the untranslated 
regions of mRNA and consequently competing with 
factors involved in mRNA degradation. Transcripts 
with PTB-mediated increased stability include those f 
insulin, VEGF (vascular endothelial growth factor), 
CD154 (cluster of differentiation 154) and iNOS 
(inducible nitric oxide synthase). 
Viral translation and replication:  PTBP1 acts as an 
ITAF (IRES -internal ribosomal entry site- trans-acting 
factor) for mRNA translation of virus belonging to the 
Picornaviridae family and lacking cap structure. PTB 1 
seems to have a role as a viral RNA chaperone that 
stabilizes or alters IRES structure to direct ribosomes to 
the correct start codon. 
IRES-mediated translation: PTBP1 favours cap-
independent translation of few cellular RNAs under 
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cell stress, apoptosis or infection through ribosome 
recruitment to IRES. In this case, PTBP1 cytoplasmic 
relocalisation is required. 
Homology 
PTBP1 shares 70-80% homology with two other 
proteins: nPTB (neural PTB), expressed in adult brain, 
muscle and testis, and ROD1 (regulator of 
differentiation 1) only expressed in hematopoietic cells. 
PTB also regulates alternative splicing of its 
homologues, in particular the nonsense-mediated decay 
of nPTB transcripts and the non-productive splicing of 
ROD1 (Sawicka et al., 2008). 
Mutations 
Somatic 
Three synonymous mutations have been reported in 
cancer samples: c.510C>T (p.A170A) in kidney 
carcinoma (Dalgliesh et al., 2010), c.1416C>T 
(p.F472F) in melanoma (Wei et al., 2011) and 
c.501G>A (p.S167S) in squamous cell carcinoma of 
the mouth (Stransky et al., 2011). Moreover five 
missense mutations have been identified in other cancer 
samples: c.932C>T (p.A311V) in ovarian carcinoma 
(Cancer Genome Atlas Research Network, 2011), 
c.413C>T (p.T138I) in skin squamous cell carcinoma 
(Durinck et al., 2011), c.212C>T (p.T71M), c.666C>G 
(p.F222L) and c.928G>A (p.G310R) in squamous cell 
carcinomas of the mouth and larynx (Durinck et al.,




PTBP1 is aberrantly overexpressed in glioma with 
expression levels correlated with glial cell 
transformation. The increased expression of PTBP1 
contributes to gliomagenesis by deregulating the 
alternative splicing of genes involved in cell 
proliferation and migration (McCutcheon et al., 2004; 
Cheung et al., 2006; Cheung et al., 2009).  
FGFR-1 (fibroblast growth factor receptor-1): PTBP1 
overexpression increases FGFR-1 α exon skipping and 
hence the synthesis of a receptor with higher affinity 
for fibroblast growth factor, favouring transformed cell 
growth (Jin et al., 2000). 
PKM (pyruvate kinase): PTBP1 overexpression leads 
to the re-expression of the embryonic pyruvate kinase 
isoform, PKM2, in transformed glial cells. The switch 
from PKM1, normally expressed in terminally 
differentiated cells, to PKM2 is achieved through the 
PTBP1-mediated inclusion in the PKM mRNA of exon 
10, instead of exon 9. In transformed cells PKM2 
promotes aerobic glycolysis and proliferation. Recently 
c-Myc overexpression has been demonstrated to 
upregulate PTBP1 transcription in transformed glial 
cells (David et al., 2010). 
USP5 (ubiquitin specific peptidase 5): PTBP1 
overexpression in GBM forces the expression of USP5 
isoform 2, a protein involved in ubiquitination. USP5 
isoform 2 has a low activity and favours cell growth 
and migration (Izaguirre et al., 2011). 
Ovarian tumour 
Note 
PTBP1 is overexpressed in the majority of epithelial 
ovarian tumours and deregulates cell proliferation, 
anchorage-dependent growth and invasiveness. PTBP1 
targets in ovarian transformed cells have not yet been 
identified (He et al., 2007). 
Alzheimer's disease (AD) 
Note 
Recent evidences delineate PTBP1 as a regulator of he 
amyloid precursor protein (APP) in neurons. In 
particular, PTBP1 altered expression in neuronal cells, 
likely mediated by miR-124, enhances the expression 
of APP isoforms including exon 7 and/or 8. These 
isoforms have been found enriched in AD patients and 
associated with β-amyloid production (Smith et al., 
2011). 
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